Literature DB >> 18608610

Extended follow-up of a randomized controlled trial of the Lidcombe Program of Early Stuttering Intervention.

Mark Jones1, Mark Onslow, Ann Packman, Sue O'Brian, Anna Hearne, Shelley Williams, Tika Ormond, Ilsa Schwarz.   

Abstract

BACKGROUND: In the Lidcombe Program of Early Stuttering Intervention, parents present verbal contingencies for stutter-free and stuttered speech in everyday situations. A previous randomized controlled trial of the programme with preschool-age children from 2005, conducted in two public speech clinics in New Zealand, showed that the odds of attaining clinically minimal levels of stuttering 9 months after randomization were more than seven times greater for the treatment group than for the control group. AIMS: To follow up the children in the trial to determine extended long-term outcomes of the programme. METHODS & PROCEDURES: An experienced speech-language therapist who was not involved in the original trial talked with the children on the telephone, audio recording the conversations using a telephone recording jack. Parental reports were gathered in addition to the children's speech samples in order to obtain a balance of objective data and reports from a wide range of situations. OUTCOMES &
RESULTS: At the time of this follow-up, the children were aged 7-12 years, with a mean of 5 years post-randomization in the 2005 trial. Twenty of the 29 children in the treatment arm and eight of the 25 children in the control (no treatment) arm were able to be contacted. Of the children in the treatment group, one (5%) failed to complete treatment and 19 had completed treatment successfully and had zero or near-zero frequency of stuttering. Three of the children (16%) who had completed treatment successfully had relapsed after 2 or more years of speech that was below 1% syllables stuttered. Meaningful comparison with the control group was not possible because an insufficient number of control children were located and some of them received treatment after completing the trial. CONCLUSIONS & IMPLICATIONS: The majority of preschool children are able to complete the Lidcombe Program successfully and remain below 1% syllables stuttered for a number of years. However, a minority of children do relapse and will require their parents to reinstate the treatment procedures.

Entities:  

Mesh:

Year:  2008        PMID: 18608610     DOI: 10.1080/13682820801895599

Source DB:  PubMed          Journal:  Int J Lang Commun Disord        ISSN: 1368-2822            Impact factor:   3.020


  6 in total

1.  [Speech fluency disorders in childhood and adolescence].

Authors:  K Neumann
Journal:  HNO       Date:  2019-07       Impact factor: 1.284

2.  The Pathogenesis, Assessment and Treatment of Speech Fluency Disorders.

Authors:  Katrin Neumann; Harald A Euler; Hans-Georg Bosshardt; Susanne Cook; Patricia Sandrieser; Martin Sommer
Journal:  Dtsch Arztebl Int       Date:  2017-06-05       Impact factor: 5.594

Review 3.  Non-pharmacological interventions for stuttering in children six years and younger.

Authors:  Åse Sjøstrand; Elaina Kefalianos; Hilde Hofslundsengen; Linn S Guttormsen; Melanie Kirmess; Arne Lervåg; Charles Hulme; Kari-Anne Bottegaard Næss
Journal:  Cochrane Database Syst Rev       Date:  2021-09-09

Review 4.  The state of the art in non-pharmacological interventions for developmental stuttering. Part 1: a systematic review of effectiveness.

Authors:  Susan Baxter; Maxine Johnson; Lindsay Blank; Anna Cantrell; Shelagh Brumfitt; Pam Enderby; Elizabeth Goyder
Journal:  Int J Lang Commun Disord       Date:  2015-06-30       Impact factor: 3.020

5.  Clinical Characteristics Associated With Stuttering Persistence: A Meta-Analysis.

Authors:  Cara M Singer; Alison Hessling; Ellen M Kelly; Lisa Singer; Robin M Jones
Journal:  J Speech Lang Hear Res       Date:  2020-08-10       Impact factor: 2.297

6.  Direct versus Indirect Treatment for Preschool Children who Stutter: The RESTART Randomized Trial.

Authors:  Caroline de Sonneville-Koedoot; Elly Stolk; Toni Rietveld; Marie-Christine Franken
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.